In the news

GlycoBac announces partnership with MilliporeSigma

GlycoBac has partnered with MilliporeSigma to facilitate the distribution of our Sf-RVN cell line for commercial vaccine and gene therapy vector production. In addition to distributing Sf-RVN cells through a cGMP cell bank, MilliporeSigma will offer a chemically defined medium formulation specially designed for Sf-RVN cells. See the announcement from MilliporeSigma

GlycoBac has been featured in several media reports:

GlycoBac Receives NIH Grant to Expand Research of Glycoprotein Drugs

(University of Wyoming, April 1 2014)

UW biotech business gets $1M bump 

(Wyoming business report, October 18, 2012)

Biotech company one of newest to come from UW 

(Casper star Tribune, April 22 2012)

UW Professor’s Company, UW Sign Agreement to Commercialize Research 

(University of Wyoming, February 22 2012)

Laramie, Wyo., company receives funds to continue protein research for medical applications 

(Wyo Business Council, Dec 2011)

UW Student Entrepreneurs Tie for First in $10K Competition (March 30, 2011)